‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges
Doctors are now confident they can detect and treat the rare blood clotting syndrome associated with AstraZeneca ’s vaccine, with just one death recorded so far.
When the syndrome, known as thrombosis with thrombocytopenia (TTS), was first identified one in four people with it died.
But the fatality rate has been dropping in Europe, where it was first identified. As of last Thursday, Australia had recorded 31 confirmed and 10 probable cases.
Of those cases, 23 are out of hospital and recovering, four require ongoing care and 13 remain in hospital.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more